Table 5. Numbers of Hepatocellular Carcinomas and Biliary Tract Cancers Before and During the COVID-19 Pandemic.
Cancer stage | Cumulative, No. | Per month, mean (SD) | Change, % | P value | ||
---|---|---|---|---|---|---|
Before | During | Before | During | |||
Hepatocellular carcinoma | ||||||
Total | 338 | 75 | 8.89 (3.17) | 7.50 (2.27) | −15.68 | .20 |
Stage I | 185 | 33 | 4.87 (2.28) | 3.30 (2.06) | −32.22 | .06 |
Stage II | 70 | 17 | 1.84 (1.72) | 1.70 (1.49) | −7.71 | .81 |
Stage III | 51 | 16 | 1.34 (1.12) | 1.60 (1.71) | 19.22 | .66 |
Stage IV | 32 | 9 | 0.84 (0.92) | 0.90 (1.10) | 6.88 | .87 |
Localizeda | 286 | 59 | 7.53 (2.76) | 5.90 (2.08) | −21.61 | .09 |
Regionala | 30 | 12 | 0.79 (0.94) | 1.20 (0.59) | 52.00 | .33 |
Distanta | 22 | 4 | 0.58 (0.76) | 0.40 (0.70) | −30.91 | .50 |
Biliary tract cancer | ||||||
Total | 268 | 62 | 7.05 (3.06) | 6.20 (2.25) | −12.09 | .42 |
Stage 0 | 13 | 3 | 0.34 (0.52) | 0.30 (0.68) | −12.31 | .85 |
Stage I | 49 | 11 | 1.29 (1.41) | 1.10 (0.99) | −14.69 | .69 |
Stage II | 70 | 23 | 1.84 (1.48) | 2.30 (1.64) | 24.86 | .40 |
Stage III | 59 | 12 | 1.55 (1.37) | 1.20 (1.03) | −22.71 | .45 |
Stage IV | 77 | 13 | 2.03 (1.64) | 1.30 (1.16) | −35.84 | .20 |
Localizedb | 103 | 25 | 2.71 (1.89) | 2.50 (1.90) | −7.77 | .76 |
Regionalb | 92 | 25 | 2.42 (1.46) | 2.50 (0.85) | 3.26 | .87 |
Distantb | 73 | 12 | 1.92 (1.58) | 1.20 (1.23) | −37.53 | .19 |
Hepatocellular carcinoma was categorized as localized stage (stage IA, IB, II, or IIIA), regional stage (stage IIIB or IVA), or distant stage (stage IVB).
Gallbladder cancer was categorized as localized stage (stage 0, IA, IB), regional stage (stage IIA, IIB, IIIA, IIIB, or IVA), or distant stage (stage IVB). Hilar cholangiocarcinoma was categorized as localized stage (stage 0 or I), regional stage (stage II, IIIA, IIIB, IIIC, or IVA), or distant stage (stage IVB). Distal cholangiocarcinoma was categorized as localized stage (stage 0, I, or IIA), regional stage (stage IIB, IIIA, or IIIB), or distant stage (stage IV).